← Leaderboards
Theresa Deisher
Avm Biotechnology, Llc
$5,458,747
Attributed
$5,458,747
Total exposure
6
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $2.1M · FY2019–25$2.5M$1.9M$1.3M$625K$0
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$5,458,747 · 6
By mechanism
R44$4,623,737 · 3
R43$835,010 · 3
Top collaborators
No co-investigators on record.
Others in their field
Other Emerging Leaders on “Dose”
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$124,321,134
- Beth Baseler · Leidos Biomedical Research, Inc.$52,807,683
- Susan Abushakra · Alzheon, Inc.$47,265,244
- Paula Gonzalez-Maya · Fundacion Inciensa$37,578,679
- Xinhua Li · Nano Terra, Inc.$35,520,438
- Jeffrey Reich · Sparian Biosciences, Inc.$28,575,028
Research focus
DoseDexamethasoneFormulationBiotechnologyPre-ClinicalChemotherapyRegimenToxic EffectRelapseSafetyPreventClinical TrialsSide EffectS LymphomaCellsSmall Business Innovation Research GrantRefractoryDesignMedicalInnovationNon-Hodgkin&AposNovel StrategiesExcipientsPharmaceutical Preparations
Grant awards (8)
Immunomodulatory AVM0703 to bridge Relapsed/Refractory Diffuse Large B-Cell Lymphoma patients to CAR-T cell immunotherapy$992,425
R44 · FY2025 · CA · contact PI
Expedited Expansion Cohort Clinical Trial for Relapsed/Refractory 'no-option' Non-Hodgkin's Lymphoma/Leukemia Patients$999,999
R44 · FY2023 · CA · contact PI
Targeted Lymphoablation as an alternative to HSCT to cure T1D$963,581
R44 · FY2023 · DK · contact PI
Expedited Expansion Cohort Clinical Trial for Relapsed/Refractory 'no-option' Non-Hodgkin's Lymphoma/Leukemia Patients$999,999
R44 · FY2022 · CA · contact PI
Targeted Lymphoablation as an alternative to HSCT to cure T1D$667,733
R44 · FY2022 · DK · contact PI
AVM0703 combined with Non-Hodgkin's Lymphoma standard of care to enhance complete response rates without additional toxicities$399,193
R43 · FY2022 · CA · contact PI
A novel non-toxic preconditioning regimen for cancer cell therapy$224,770
R43 · FY2020 · CA · contact PI
Targeted lympho-ablation as an alternative to HSCT to cure T1D$211,047
R43 · FY2019 · DK · contact PI